Jonathan P. Graham, Executive Vice President and General Counsel at Amgen Inc . (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $158 billion and "GOOD" financial ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Shares of Amgen Inc. AMGN shed 1.42% to $293.54 Friday, on what proved to be an all-around dismal trading session for the ...

The market seemed to focus on the sales, and the stock traded up as a result. The shares closed the day at $307.92, up 6.5% from previous close. Is now the time to buy Amgen? Access our full ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...